Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 13Phase 3 11Phase 1/2 9Phase NA 5Phase 2/3 3Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 34Thoracic 23Head & Neck 17Genitourinary 16Gynecologic 12Breast 12Other hematologic neoplasm 9Lymphoid 8Dermatologic 6Sarcoma 5Endocrine 5CNS 5Tumor-Agnostic 4NET 3Myeloid 3Plasma cell 2Other solid neoplasm 1Other 1Classical hematology 1

Conditions

Neuroendocrine Tumors 2Neoplasm Metastasis 1Gastroenteropancreatic Neuroendocrine Tumors 1Adenoma, Islet Cell 1

Interventions

Everolimus 2Sirolimus 1Injections 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × NET × 90 days × Clear all
NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡